Britain and America have announced a major trade agreement that will guarantee no duties on British drug exports entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to boost funding on medicines through the public health system. This pledge guarantees that import taxes on these vital products will be held at zero for a timeframe of 36 months.
This deal comes after previous statements to dramatically increase duties on patented pharmaceutical imports, with increases mentioned as high as one hundred percent.
"This arrangement with the United Kingdom reinforces the international landscape for innovative medicines and brings long-overdue equity to U.S.–U.K. medicine commerce," a statement noted.
Commercial Significance
Medicines are one of the the United Kingdom's largest goods shipped to the US, which is easily the primary market for major UK drugmakers.
Trade data indicate that in the one-year period prior to the third quarter, the UK shipped medicines worth £11.1bn to the US. This figure made up 17.4% of British export trade in that period.
"This agreement protects jobs, increases investment and facilitates the UK to emerge as a international leader for biotech and pharma," a government official stated.
Key British Pledges
The agreement involves several specific commitments from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to raise overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must return to the NHS to control costs will be restricted at 15%. Previously, refunds topped 20%.
Broader Context
The pact comes amid a long-running tension between the sector and the UK government over spending levels and approval rates.
These tensions were exacerbated by assertions that American consumers were charged significantly more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or abandoned, while major investments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to spend more on medicines, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
